Schiano di Visconte Michele, Bellio Gabriele
Colorectal and Pelvic Floor Diseases Center, Department of General Surgery, "S. Maria dei Battuti" Hospital, Via Brigata Bisagno 4, 31015, Conegliano, TV, Italy.
Int J Colorectal Dis. 2018 Dec;33(12):1723-1731. doi: 10.1007/s00384-018-3154-z. Epub 2018 Sep 5.
Rectal advancement flap is the standard surgical treatment for complex cryptoglandular anal fistulas, while Permacol™ collagen paste is considered an innovative treatment option for anorectal fistulas. This study aimed to compare the clinical outcomes of patients with complex cryptoglandular fistulas treated by endorectal advancement flap versus Permacol™ paste.
This study was a retrospective analysis of patients with complex cryptoglandular anal fistulas. Thirty-one patients were treated with the rectal advancement flap (RAF group), while 21 were treated with Permacol™ paste injection (PP group). In PP group, the approach consisted of loose seton positioning followed several weeks later by closure internal opening with a resorbable sutures associated with paste injection into the fistula track. Clinical outcomes were assessed in terms of healing rate, faecal continence and patient satisfaction.
Seton drainage was done in all patients in both groups for a median duration of 8 weeks (range 4-18 weeks) before the final surgery (p = 0.719). No patient had faecal incontinence (CGS ≥ 5) preoperatively. Five patients (16%) in the RAF group and one (5%) in the PP group experienced faecal incontinence postoperatively. The 2-year disease-free survival was 65% in the RAF group and 52% in the PP group (p = 0.659). The median satisfaction scores were 5 (range 1-10) in the RAF group and 7 (range 2-10) in the PP group (p = 0.299).
The RAF appeared superior to PP in terms of fistula healing, although this result was not statistically significant. On the contrary, PP has a potential advantage in terms of continence disorders. Permacol™ paste can be considered as the initial treatment option for complex cryptoglandular anal fistulas in patients with faecal continence disorders.
直肠推进皮瓣术是复杂性隐窝腺性肛瘘的标准外科治疗方法,而Permacol™胶原蛋白糊剂被认为是肛瘘的一种创新治疗选择。本研究旨在比较经直肠推进皮瓣术与Permacol™糊剂治疗复杂性隐窝腺性肛瘘患者的临床疗效。
本研究是对复杂性隐窝腺性肛瘘患者的回顾性分析。31例患者接受直肠推进皮瓣术(RAF组),21例患者接受Permacol™糊剂注射治疗(PP组)。在PP组中,治疗方法包括宽松挂线定位,几周后用可吸收缝线封闭内口,并将糊剂注入瘘管。根据愈合率、大便失禁情况和患者满意度评估临床疗效。
两组所有患者在最终手术前均进行了挂线引流,中位持续时间为8周(范围4-18周)(p = 0.719)。术前无患者出现大便失禁(CGS≥5)。RAF组5例(16%)患者和PP组1例(5%)患者术后出现大便失禁。RAF组2年无病生存率为65%,PP组为52%(p = 0.659)。RAF组中位满意度评分为5分(范围1-10分),PP组为7分(范围2-10分)(p = 0.299)。
尽管该结果无统计学意义,但在瘘管愈合方面,RAF似乎优于PP。相反,PP在大便失禁方面具有潜在优势。对于有大便失禁问题的复杂性隐窝腺性肛瘘患者,Permacol™糊剂可被视为初始治疗选择。